Cracking the Bone Code: Why Osteoporosis Meds Aren't Always the Answer
"Uncover the Hidden Reasons Behind Medication Hesitancy and How to Make Informed Choices for Bone Health"
When it comes to osteoporosis, the path to treatment isn't always straightforward. Medication decision-making is a complex process. It involves multiple considerations beyond just a doctor's prescription.
This decision starts with whether to take the medication and continues throughout care. Primary adherence determines the decision to start a medication, and secondary adherence concerns the decision to stop.
Many patients do not start osteoporosis medication, even with a high risk of fractures. Studies show only a percentage of high-risk individuals take the medication prescribed. Even when cost isn't an issue, a significant number of people never fill their prescriptions.
Adherence and Fracture Prevention
A 2024 review describes poor medication adherence as a major concern in osteoporosis care and identifies fragility fractures as the main consequence of osteoporosis. It reports that available treatments reduce vertebral, hip, and other fractures by 30%–70%, depending on the drug and fracture site. A 2013 study compared physicians’ estimates of adherence with pharmacy-claims adherence among women aged 45 and older, but the provided source summaries do not give its adherence results.
What Shapes Treatment Adherence
The 2018 systematic review identified polypharmacy, older age, and misconceptions about osteoporosis as factors associated with poorer adherence to anti-osteoporotic therapy. A 2022 study describes the Activating Patients at Risk for OsteoPOroSis (APROPOS) educational intervention, developed for women with a history of fracture who reported not currently receiving osteoporosis medication. Together, these sources focus on adherence barriers and patient education rather than tracing discoveries in osteoporosis treatment.
Decoding the Risk Perception Puzzle
Patients weigh the perceived risks against the perceived benefits when deciding about medications. Although risk involves outcome probability, individuals interpret it uniquely.
- Information Sources: Doctor, pharmacist, media.
- Immediacy: How recently you heard it.
- Biases: Preconceived notions.
- Framing: The way information is presented.
- Emotions: Feelings about the medication or condition.
- Denial: Refusal to accept the risk.
- Disease Perception: How you view osteoporosis.
Research Gaps in Long-Term Therapy
The National Institutes of Health convened its Pathways to Prevention workshop on October 30–31, 2018, to review evidence on using drug therapies for more than three years to prevent osteoporotic fractures and identify research gaps. The workshop source notes that people may overestimate the risk of rare medication adverse effects while underestimating their fracture likelihood. An ESCEO and International Osteoporosis Foundation expert group recommends understanding whether non-adherence involves initiation, implementation, or persistence, measuring it, and identifying and addressing its cause.
Patient and Practice Barriers
A qualitative study examined decisions about osteoporosis medication among English-speaking outpatients aged 65 and older who had sustained a fragility fracture within the previous five years, were classified as high risk for another fracture, and had been prescribed medication. Its eligibility criteria included people with and without prior osteoporosis treatment, but the provided summary does not report the study’s findings. A study published in 2026 set out to explore clinician, patient, and commissioner views on pharmacist-led medication reviews, including information needs and implementation barriers and facilitators; the available summary does not state its results.
Why Patients Stop or Decline Therapy
A survey finding cited in a study of patient-reported barriers found that concern over side effects was the primary reason for not starting osteoporosis therapy among U.S. women aged 55 and older, reported by 77.3% of respondents. Separately, a study of adults aged 66 and older in Ontario found that within two years of starting therapy, 54% discontinued it, and 70% of those who discontinued later restarted. These findings describe different populations and outcomes—reasons for not initiating treatment versus discontinuation and reinitiation—so they should not be treated as directly comparable rates.
Empowering Informed Choices for Bone Health
Better results will come with greater understanding. Individuals need to appreciate the real risks of NOT taking medication, compared to the perceived side effects. The path forward involves open communication and patient education.
A Nuanced View of Osteoporosis Trends
A 2025 article calls for a nuanced understanding of osteoporosis trends and their implications for aging research and healthcare policy. It highlights the interplay between medicalization, pharmaceutical influence, and societal perceptions. The provided source summary does not specify particular future treatments or forecast figures.
Adherence in Real-World Care
A systematic review examined patient adherence and persistence with oral bisphosphonates for osteoporosis in real-world settings. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach and searched databases including MEDLINE and CINAHL. The available source summaries describe the review’s purpose and methods but do not provide its adherence or persistence estimates.